Safety Study of ARQ 197 in Cirrhotic Patients With Hepatocellular Carcinoma (HCC)
Multi-center, single-arm Phase 1b study designed to evaluate safety and tolerability of ARQ 197 in cirrhotic patients with HCC.
Cirrhosis|Hepatocellular Carcinoma
DRUG: ARQ 197
To evaluate the safety of ARQ 197 when administered in cirrhotic patients diagnosed with HCC
To evaluate time to disease progression (TTP), objective response rate (ORR), and disease control rate (DCR) in patients with HCC|To evaluate dynamic changes of hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), and soluble c-Met in patients' peripheral blood that are associated with ARQ 197 treatment
Study designed to evaluate safety and tolerability of ARQ 197 in cirrhotic patients with HCC who have received â‰¤2 prior systemic regimens for HCC, and whose liver disease severity is categorized as Class A and B per Child-Pugh Classification.